# Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

> **NCT05553093** · PHASE4 · RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 150 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT05553093
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05553093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05553093, "Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05553093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*